Antibiotic Use Among Children Under Two Years With Respiratory Syncytial Virus Infection at Korle Bu Teaching Hospital, Ghana.

This cross-sectional study at Korle Bu Teaching Hospital reveals that two-thirds of children under two with confirmed Respiratory Syncytial Virus (RSV) infection received antibiotics, primarily driven by markers of disease severity rather than bacterial co-infection, highlighting an urgent need for improved diagnostics and antimicrobial stewardship in Ghana.

The Gist

Imagine a tiny, invisible invader called Respiratory Syncytial Virus (RSV). It's like a mischievous ghost that sneaks into the lungs of babies and toddlers, causing them to cough, wheeze, and struggle to breathe. In many parts of the world, doctors have special "ghost detectors" (rapid tests) to see if the ghost is there. But in places like Ghana, these detectors are rare.

Because they can't see the ghost, doctors often have to guess. When a baby comes in with a bad cough and trouble breathing, it's hard to tell if it's just the virus (which antibiotics can't kill) or a bad bacteria (which antibiotics can kill).

Here is the story of what happened at the Korle Bu Teaching Hospital in Ghana:

The Big Mix-Up

The researchers went to the hospital and looked at 128 little patients under the age of two who were sick with breathing problems. They used a special, high-tech test to check for the RSV ghost.

• The Result: They found the ghost in 72 of the children (about 56%).
• The Problem: Even though they knew these 72 kids had a virus, 48 of them (two out of three!) were still given antibiotics.

Think of it like this: If your house is on fire because of a lightning strike (the virus), giving it a bucket of water (antibiotics) won't help. You need a fire extinguisher designed for electrical fires, or you just need to wait for the storm to pass. Antibiotics are like a bucket of water for a fire caused by a lightning strike—they do nothing for the virus but might accidentally damage the house (the child's body) in the process.

Why Did This Happen?

The study found that the doctors weren't just guessing randomly; they were reacting to how sick the babies looked.

• The "Scary" Signs: Babies who were given antibiotics were the ones who were really struggling—breathing very fast, having low oxygen, or needing to stay in the hospital.
• The Fear: When a baby looks that sick, doctors are terrified of missing a hidden bacterial infection (like a secondary infection hiding behind the virus). So, they play it safe and prescribe antibiotics "just in case."

However, when the researchers looked closely, they found that only 11 of the 48 babies actually had a bacterial infection that needed antibiotics. The other 37 babies were given medicine they didn't need.

The Cost of "Just in Case"

Why does this matter? Imagine you have a key that opens every door in a building. If you use that key on every door, even the ones that are already open, eventually, the locks get jammed, and the key stops working.

• Antibiotic Resistance: When we use antibiotics too much, the "bad bacteria" learn how to hide from them. They become "superbugs" that the medicine can no longer kill.
• The Gut Garden: Antibiotics are like a forest fire inside a child's tummy. They burn up the bad bacteria, but they also burn the good bacteria that help the child stay healthy. This can mess up their digestion and immunity for months.

The Solution: Better Tools and New Shields

The paper suggests three main ways to fix this:

1. Better Detectors (Rapid Diagnostics): If doctors had those "ghost detectors" right at the bedside, they could say, "Okay, it's definitely the virus. No need for antibiotics." This would stop the guesswork.
2. The "Watch List" (Stewardship): Doctors need to be careful about which antibiotics they use. The study found they were using "Watch" group antibiotics (strong, broad-spectrum ones) too often. They should stick to the "Access" group (gentler, more targeted ones) unless absolutely necessary.
3. Prevention (The Shield): The best way to stop the problem is to stop the virus from getting in the first place. The paper suggests giving vaccines to pregnant moms or special antibodies to babies. If the baby doesn't get sick with RSV, they won't need antibiotics at all.

The Takeaway

This study is a wake-up call. It shows that in places where high-tech tests are hard to get, doctors are forced to guess, and they often guess wrong by giving too many antibiotics.

To protect our children and keep antibiotics working for when we really need them, we need better tools to see the virus, smarter rules for doctors, and vaccines to stop the virus before it starts. It's about moving from "guessing and hoping" to "knowing and preventing."

Technical Summary

1. Problem Statement

Respiratory Syncytial Virus (RSV) is a leading cause of lower respiratory tract infections (LRTIs) and hospitalization in infants. In low-resource settings (LRS) like Ghana, the lack of routine rapid diagnostic tools creates a clinical overlap between viral RSV bronchiolitis and bacterial pneumonia. Consequently, clinicians often prescribe antibiotics empirically to avoid missing bacterial co-infections. This practice contributes significantly to the global crisis of Antimicrobial Resistance (AMR). The study addresses the gap in data regarding the frequency and clinical drivers of unnecessary antibiotic use in RSV-positive children within a tertiary care setting in Ghana.

2. Methodology

• Study Design: Cross-sectional analysis conducted between June and November 2023 (RSV seasonal peak).
• Setting: Department of Child Health (DCH) at Korle Bu Teaching Hospital (KBTH), Accra, Ghana—a major tertiary referral center.
• Population: 128 children under two years of age presenting with acute respiratory illness (ARI) meeting WHO case definitions for (severe) ARI.
• Diagnostic Protocol:
  • Primary Screening: Nasal swabs tested using a molecular Point-of-Care (POC) device (ID NOW®).
  • Confirmatory Testing: All samples underwent Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR) at the Noguchi Memorial Institute for Medical Research (NMIMR).
  • Note: 14 cases initially negative by POC were confirmed positive by RT-PCR and included in the analysis.
• Data Collection: Structured questionnaires and electronic medical record abstraction captured demographics, clinical signs (tachypnea, hypoxia, dyspnea), antibiotic prescriptions, and co-infections.
• Antibiotic Classification: Prescriptions were categorized using the WHO AWaRe system (Access, Watch, Reserve).
• Statistical Analysis: Descriptive statistics, Mann-Whitney U tests (for medians), and Chi-squared/Fisher's exact tests (for categorical variables). Multivariable logistic regression was planned to identify determinants.

3. Key Results

• Prevalence: Out of 128 enrolled children, 72 (56.2%) were confirmed RSV-positive.
• Antibiotic Usage: Among the 72 RSV-positive children, 48 (66.7%) received antibiotics during their illness.
• Clinical Determinants of Antibiotic Use: Antibiotic prescription was significantly associated with markers of disease severity:
  • Hypoxia: $p = 0.009$
  • Tachypnea: $p = 0.015$
  • Dyspnea (Difficulty breathing): $p < 0.001$
  • Hospital Admission: $p < 0.001$
• Co-infection Status: Only 11 (23%) of the antibiotic-treated RSV-positive children had suspected or confirmed bacterial co-infections (e.g., sepsis, UTI, gastroenteritis). The remaining 77% received antibiotics without evidence of bacterial co-infection.
• Antibiotic Types:
  • Frequency: Penicillins were the most prescribed (48.7%), followed by third-generation cephalosporins (21.8%).
  • AWaRe Classification: 74.36% of prescriptions fell under the "Watch" group (broad-spectrum antibiotics with higher resistance potential), while 25.64% were "Access" group.
• Demographics: RSV-positive children were significantly younger (median age 2.9 months) compared to RSV-negative children (median 5.1 months).

4. Key Contributions

• Quantification of Overuse: The study provides empirical evidence that two-thirds of RSV-positive infants in a Ghanaian tertiary hospital receive antibiotics, with the vast majority lacking bacterial co-infections.
• Severity vs. Etiology: It highlights that clinical severity (hypoxia, tachypnea) is a stronger driver for antibiotic prescription than confirmed bacterial etiology, indicating a reliance on empirical treatment due to diagnostic uncertainty.
• AWaRe Analysis: The finding that nearly 75% of prescriptions were "Watch" group antibiotics (e.g., third-generation cephalosporins) underscores a high risk of driving resistance in a setting where second-line treatments are scarce.
• Diagnostic Stewardship: The study demonstrates the feasibility and impact of using molecular POC and RT-PCR to confirm viral etiology, suggesting that such tools could inform better decision-making if integrated into routine care.

5. Significance and Implications

• Antimicrobial Stewardship (ASP): The findings strongly advocate for the implementation of ASPs in pediatric departments in Ghana. These programs must include clear clinical pathways for viral illnesses and training to reduce empirical prescribing based solely on severity markers.
• Diagnostic Capacity: There is an urgent need to scale up rapid diagnostic testing (POC/PCR) in LRS to distinguish viral from bacterial infections at the bedside, reducing the "fear of missing" bacterial sepsis.
• Preventive Strategy: The study reinforces the WHO recommendation for RSV prevention via maternal vaccination or infant monoclonal antibodies (nirsevimab). Preventing severe RSV cases would directly reduce the volume of hospitalizations and the subsequent unnecessary antibiotic exposure.
• Global Health Context: In Low- and Middle-Income Countries (LMICs), where the burden of AMR is high and treatment options are limited, reducing inappropriate antibiotic use in children is critical for preserving the efficacy of existing antibiotics.

Conclusion: The study concludes that while clinical severity drives antibiotic use in RSV cases, the lack of bacterial confirmation suggests widespread inappropriate prescribing. Addressing this requires a multi-faceted approach combining rapid diagnostics, stewardship programs, and preventive immunization strategies.